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Abstract 
 
Green Tea Extract, Epigallocatechin Gallate, Protect Against  
Methamphetamine-Induced Striatal Neurotoxicity in Mice  
By 
Allen L. Pan 
Advisor: Professor Jesus A. Angulo 
Methamphetamine (METH) is a strong psychostimulant and its exposure can lead to 
serious neurological complications. METH-induced neuronal injury is the result of a complex 
interplay of different factors including dopamine (DA) overflow, oxidative stress and 
neuroinflammation. Although the mechanisms of METH-induced neurotoxicity have been 
extensively studied, there is still no effective therapeutic treatment. Therefore, it is essential to 
study potential drug candidates that can treat METH-induced neurotoxicity. Green tea extract, 
epigallocatechin gallate (EGCG), has emerged as a neuroprotective agent that can protect against 
several neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. Recently, our 
lab has shown that EGCG prevents the METH-induced apoptosis and dopamine terminal damage, 
but the mechanisms involved remain unclear. In the present study, we examined the 
neuroprotective effects of EGCG on the METH-induced striatal neuroinflammation and oxidative 
stress in mice. CD-1 Mice were given a single injection of EGCG (2 mg/kg, ip) 30 minutes prior 
to a single injection of METH (30 mg/kg, ip) and sacrificed 8 hr, 1 day, or 3 days after the METH 
injection. The results show that METH induced dopaminergic axonal neurotoxicity and 
hyperthermia reflected as a marked decrease of striatal tyrosine hydroxylase (TH) protein level 
and increase of core body temperature, respectively. EGCG prevented the METH-induced 
reduction of TH, but failed to affect the METH-induced hyperthermic response. To examine the 
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effect of EGCG on the METH-induced oxidative stress, we quantified the glutathione peroxidase 
(GPx) activity and glutathione peroxidase 4 (GPx-4), and copper-zinc superoxide dismutase 
(SOD-1) and catalase (CAT) protein levels. Colorimetric analysis indicates that METH decreased 
GPx activity 1 day after METH injection, this result is correlated to the reduction of GPx-4 protein 
level caused by METH as demonstrated by Western blots. In addition, Western blot analysis shows 
that METH increased SOD-1 and CAT proteins level 8 hr and 1 day after METH injection, 
respectively. Finally, immunohistochemical staining and Western blotting were used to evaluate 
the changes of glial activation, cycloocygenase-2 (COX-2) and blood-brain barrier (BBB) in the 
striatum. The results show that METH induced microglial activation and increase of COX-2 
expression 1 day after METH injection as indicated by increase of Iba-1 and COX-2 
immunoreactivity, respectively. These effects were followed by the increase of astrocytic 
activation and compromise of the blood-brain barrier (BBB) 3 days after the METH injection. 
Pretreatment with EGCG failed to prevent these effects, instead EGCG potentiated the METH-
induced increase of glial activations and COX-2 protein level. Nevertheless, EGCG prevented the 
METH-induced breakdown of BBB reflected by diminished fluorescein iosothiocynate-dextran 
(FITC-dextran) extravasation in the striatum.  Taken together, these data indicate that EGCG is 
effective in preventing the METH-induced oxidative stress and compromise of the BBB although 
it potentiates the glial response and the increase of COX-2 protein level.    
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Specific Aims 
 
Specific Aim 1: To study the neuroprotective mechanisms of EGCG on METH-induced 
oxidative stress. 
1a: To assess the effect of EGCG on glutathione peroxidase activity alteration caused by 
METH. 
Hypothesis: We expect that EGCG reduces METH-induced oxidative stress, therefore 
prevents the alteration of glutathione peroxidase activity. 
Rationale: METH is known to increase oxidative stress and affecting the normal activity 
of various endogenous antioxidative enzymes including glutathione peroxidase. METH-
induced alteration of glutathione peroxidase is also associated with depletion of glutathione 
(GSH), which is an antioxidant that works with glutathione peroxidase to reduced hydrogen 
peroxide. Since EGCG is a strong antioxidant, which should mitigate METH-induced 
oxidative stress and restore glutathione peroxidase activity. 
1b: To investigate whether EGCG prevent METH-induced reduction of glutathione 
peroxidase 4 protein level. 
Hypothesis: EGCG prevents METH-induced oxidative stress through regulation of 
glutathione peroxidase 4 protein. 
Rationale: Glutathione peroxidase 4 is one of the isozymes of glutathione peroxidase. 
Glutathione peroxidase 4 is expressed is almost all of the mammalian cells. The normal 
function of glutathione peroxidase 4 requires glutathione. However, METH depletes the 
level of glutathione and therefore, it dysregulates the level of glutathione peroxidase 4. 
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Glutathione peroxidase is suggested to indirectly involve in regulation of apoptosis through 
inhibition of 12/15 lipoxygenase, which otherwise can produce products that can trigger 
apoptotic pathway. Since our laboratory has previously shown that EGCG mitigated 
METH-induced apoptosis, it is possible that EGCG achieved this result through 
upregulation of glutathione peroxidase 4. 
1c: To investigate whether EGCG prevent the change of catalase protein level affected by 
METH. 
Hypothesis: EGCG reduces METH-induced accumulation of hydrogen peroxide through 
regulation of catalase. 
Rationale: Catalase is the endogenous antioxidative enzyme that regulates the 
accumulation of hydrogen peroxide. One of the causes of METH-induced oxidative stress 
is the accumulation of hydrogen peroxide, which can lead to lipid peroxidation and 
membrane damages. Therefore, it is reasonable to investigate the antioxidative effect of 
EGCG on METH-induced alteration of catalase protein level. 
1d: To investigate whether EGCG prevent the change of Zn superoxide dismutase 1 protein 
level affected by METH. 
Hypothesis: The antioxidative property of EGCG reduces METH-induced dysregulation 
of superoxide dismutase 1 protein level, which prevents the accumulation of superoxide 
level. 
Rationale: METH-induced oxidative stress is involved in accumulation of reactive oxygen 
species. As a result, various endogenous antioxidative enzymes are dysregulated. 
Superoxide dismutase 1 regulates the level of superoxide by converting it into hydrogen 
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peroxide, which prevents oxidative stress. EGCG is a strong antioxidant, it has been shown 
to prevent oxidative stress in the studies of different neurodegenerative diseases. Therefore, 
it has the potential to prevent METH-induced dysregulation of superoxide dismutase 1 
protein level. 
 
Specific Aim 2. To investigate the effect of EGCG on METH-induced neuroinflammation. 
2a. To test whether EGCG prevent METH-induced activation of microglia and astrocyte. 
Hypothesis: EGCG prevents METH-induced neuroinflammation by suppressing 
microglial and astrocytic activations 
Rationale: One of the pathologies for METH-induced neuroinflammation is involved in 
glial activations. Glial activations, including microglia and astrocytes, are suggested to 
contribute to METH-induced neurotoxicity. EGCG also has anti-inflammatory properties, 
which may mitigate METH-induced neuroinflammation and prevent further neuronal 
damages caused by METH.  
2b. To assess the effect of EGCG on the METH-induced increase of cyclooxygenase-2 
level. 
Hypothesis: EGCG mitigates METH-induced neuroinflammation by suppressing the 
expression of inducible cyclooxygenase, cyclooxygenase-2 level. 
Rationale: Cyclooxygenase-2 is an inducible enzyme, which involves in mediating 
inflammation. METH-induced neuroinflammation is associated with increase of 
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cyclooxygenase-2. Since EGCG possesses anti-inflammatory properties, it can potentially 
suppress METH-induced neuroinflammation by inhibiting cyclooxygenase-2 expression. 
2c. To assess the effect of EGCG on the integrity of blood-brain barrier during METH 
administration. 
Hypothesis: EGCG ameliorates METH-induced neuronal damages by preventing blood-
brain barrier degradation. 
Rationale: Several studies have shown that METH induces blood-brain barrier 
degradation. It has been suggested that METH-induced neurotoxicity may be attributed to 
its ability to compromise the blood-brain barrier. EGCG may mitigate METH-induced 
neurotoxicity by preventing blood-brain barrier degradation.  
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CHAPTER 1. INTRODUCTION 
 
Methamphetamine (METH) is an addictive psychostimulant, which can readily cross the 
blood-brain barrier and lead to serious neuronal injury. Decades of studies have revealed some of 
the METH-induced neurotoxic effects on the dopaminergic (Fibiger and McGeer, 1971, Kogan et 
al., 1976), and serotonergic systems (Hotchkiss and Gibb, 1980, Ricaurte et al., 1980). In particular, 
METH damages monoaminergic systems through, but not limited to, prolonged depletion of 
tyrosine hydroxylase (TH) (Kogan et al., 1976), tryptophan hydroxylase (Hotchkiss and Gibb, 
1980), dopamine and serotonin levels (Fumagalli et al., 1999). Studies in abstinent METH users 
using proton magnetic resonance spectroscopy provide evidence of the long-term neurotoxic effect 
of METH even years after discontinuing drug use (Ernst et al., 2000). Chronic METH usage in 
humans has been shown to increase neuropeptides in the dopamine-rich neurons and alter the 
physiology of dopaminergic neurons in the striatum (Frankel et al., 2007). In addition, METH also 
induces oxidative stress (De Vito and Wagner, 1989), blood-brain barrier (BBB) disruption 
(Mahajan et al., 2008), glial activation (Pu and Vorhees, 1993, LaVoie et al., 2004), lipid 
peroxidation (Açikgöz et al., 1998)  and triggering neuronal apoptosis (Eisch and Marshall, 1998, 
Deng et al., 2001) in various brain area including the striatum. Although many studies have been 
conducted on the mechanisms involved in the METH-induced neurotoxicity, there is still no 
effective treatment for METH. Thus, the goal of this study is to investigate the potential 
neuroprotective agents that can protect against METH-induced neurotoxicity in the striatum. To 
do so, we used epigallocatechin gallate (EGCG), a green tea extract, which has been reported to 
be effective in protecting METH-induced apoptosis and dopamine damage in the striatum (Liu et 
al., 2014). 
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1.1 Epidemiology of METH 
 
METH is one of the most popular psychostimulant due to its long-lasting effect and 
inexpensive production. Although METH has been reported as a feature of amphetamine-type 
stimulants in markets on every continent, it has dominated in East and South-East Asia and North 
America (United Nations Office on Drugs and Crime, 2013). Compared to other regions, North 
America has reported the largest amount of METH trafficking and with the consistent large 
quantity of METH seizures annually (United Nations Office on Drugs and Crime, 2016). 
According to the estimation reported in 2012, there were over 12 million people (ages 12 years 
and older) in the U.S. that used METH in their lifetimes (Substance Abuse and Mental Health 
Services Administration, 2013a). Unfortunately, the prediction of these numbers will increase in 
the future due to the increase of METH manufacture locations and trafficking routes (United 
Nations Office on Drugs and Crime, 2016). 
1.2 Mechanism of METH-induced neurotoxicity in the striatum 
 
 METH exposure can lead to long-term structural damage to regions of the brain, including 
the striatum. METH-induced neurotoxic effects are often associated with the depletion of 
dopamine, which results in severe neuronal damages (Krasnova and Cadet, 2009). The study of 
METH suggests that METH administration can compromise the BBB and increase its permeability 
(Volkow et al., 2001, Bowyer John and Ali, 2006, Kiyatkin et al., 2007). METH is also known to 
increase inflammatory responses (Sekine et al., 2008, Yamamoto and Raudensky, 2008), cause 
oxidative stress and the over-production of both reactive oxygen and nitrogen species (Cadet et al., 
2007, Narita et al., 2008a, Yamamoto et al., 2010, Kate and John, 2017) leading to neuronal cell 
death (Zhu et al., 2006c) and further damage to various brain areas. Although METH-induced 
3 
 
neurotoxicity has been studied extensively, the mechanisms are not fully understood. Here, we 
will discuss the mechanisms involved in METH-induced neurotoxicity in the striatum as they are 
known at the present time. 
1.2.1 Structure and function of the striatum 
 
The striatum is the subcortical part of the forebrain. It is the main input structure of the 
basal ganglia and it participates in motor functions, cognitive functions and rewarding behaviors. 
The striatum is mainly composed of medium-sized spiny gamma-aminobutyric acidergic 
(GABAergic) projection neurons (Kemp and Powell, 1971). These neurons represent the inhibitory 
projection to the globus pallidus and the substantia nigra pars reticulata as shown in Figure 1. In 
Figure 1, it is also shown that the activity of these neurons is determined by the inputs from 
different brain areas including cortex, amygdala, and hippocampus by glutamate transmission, and 
substantia nigra pars compacta by dopamine transmission (Swanson, 1982, Phillipson and 
Griffiths, 1985, Finch, 1996, Groenewegen et al., 1999, Britt et al., 2012). Although the 
mechanisms involving dopamine in the METH-induced neurotoxicity are not fully understood, but 
the depletion of dopamine by chronic METH suggests that it may be an important contributing 
factor to the neuronal damages. 
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Figure 1. The functions of striatum. Striatum is the main input structure of basal ganglia. 
Striatum receives inputs from cortex, amygdala, and hippocampus through glutamate transmission. 
It also receives input from substantia pars compacta (SNC) by dopamine transmission. Striatum 
sends output signal to substantia pars reticula (SNR) and globus pallidus (GP) through GABA 
transmission. (Image is adapted from (David, 2009)). 
 
1.2.2 Role of dopamine in METH-induced striatal neurotoxicity 
 
Multiple lines of evidence indicate that METH causes injury in different types of neurons 
in the striatum including dopaminergic neurons (O'Dell et al., 1993, Xu et al., 2005, Zhu et al., 
2006b). It has been shown that METH-induced striatal injury is partly due to abnormal dopamine 
release (O'Dell et al., 1993). The mechanism by which METH exerts its neurotoxic effects to the 
striatum has been extensively studied, and the possible pathways based on research studies are 
illustrated in Figure 2. The similar chemical structure of METH and dopamine allows METH to 
enter dopamine axons through passive diffusion and dopamine transporter (DAT) (Iversen, 2006). 
In the cytoplasm, METH alters the function of the vesicular monoamine transporter 2 (VMAT-2) 
causing the release of dopamine from the synaptic vesicles to the cytosol, followed by reverse 
transport of dopamine (DA) into the synaptic cleft from the cytosol through DAT (Sulzer et al., 
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2005). In addition, METH also reduces TH level and eventually depletes DA level (Wilson et al., 
1996). Thus, it is believed that DA is an important component of the METH-induced striatal 
neurotoxicity. 
Indeed, many studies show that DA plays an important role in the METH-induced striatal 
injury. For instance, METH-induced DA axonal damage in the striatum is prevented when DA 
level is decreased using TH inhibitor, -methyl-p-tyrosine (Gibb and Kogan, 1979, Hotchkiss and 
Gibb, 1980, Wagner et al., 1983, Schmidt et al., 1985, Axt et al., 1990, Thomas et al., 2008). In 
addition, increasing the DA levels by L-DOPA, an immediate precursor of dopamine, exacerbates 
the METH-induced neurotoxicity (Gibb and Kogan, 1979, Schmidt et al., 1985, Thomas et al., 
2008). On the other hand, METH has been observed to induce reactive oxygen species (ROS) 
production in normal, but not in DA-depleted, striatal synaptosomes (Pubill et al., 2005). The 
important role of DA in METH-induced neurotoxicity is further substantiated in the studies 
showing that METH-induced oxidative stress and ROS formation are only found in ventral 
midbrain cell cultures that contain DA neurons, but not in nucleus accumbens cell cultures that do 
not have DA neurons (Cubells et al., 1994). These findings support the idea that DA contributes 
to the METH-induced neurotoxicity, but it is not clear whether DA is directly involved in the 
METH-induced neuronal damages. 
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Figure 2. Pathways of METH-induced dopaminergic neurotoxicity. The figure shows the 
proposed pathways that METH enters dopaminergic terminal and induce neurotoxic effects in the 
striatum. METH crosses the neuronal terminal membrane and enters the cytoplasm through either 
dopamine transporter (DAT) or passive diffusion. In the cytoplasm, METH promotes dopamine 
release by entering the synaptic vesicles through vesicular monoamine transporter 2 (VMAT-2). 
The accumulation of dopamine leads to increase production of free radicals and ROS. 
Subsequently, it causes oxidative stress and membrane damage. METH also prevents dopamine 
reuptake from the synaptic cleft, which results in overactivation of the postsynaptic neuronal 
terminal and that leads to postsynaptic neuronal terminal damages. (Adapted from Krasnova and 
Cadet, 2009).  
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1.2.3 METH-induced oxidative stress, not dopamine release, cause neurotoxicity 
 
METH is known to promote accumulation of dopamine in the cytoplasm (Larsen et al., 
2002). The excessive dopamine in the cytoplasm rapidly oxidizes through enzymatic oxidation or 
auto-oxidation and producing reactive oxygen species (ROS) and reactive nitrogen species (RNS), 
which include dopamine quinones, superoxide, peroxide, and hydroxyl radical (Cubells et al., 1994, 
Açikgöz et al., 1998, Kita et al., 1999, LaVoie and Hastings, 1999, Stokes et al., 1999, Miyazaki 
et al., 2006). In animal studies, it has been shown that auto-oxidation of cytosolic dopamine 
increased superoxide radicals production therefore it is implicated that oxidative stress contributes 
to the METH-induced DA terminal degradation (Yamamoto and Zhu, 1998, LaVoie and Hastings, 
1999). An experiment conducted by LaVoie and Hastings showed that the dopamine oxidation 
increased in METH-treated rats at room temperature, but not at 5C, leading to increase of 
dopamine-induced protein modifications in the striatum. Further analysis showing that METH-
treated rats had same level of striatal dopamine release at both 5C and room temperature, but only 
the rats at 5C were protected against METH-induced neurotoxicity (LaVoie and Hastings, 1999). 
Together, these results are suggesting that oxidation of dopamine, not the level of dopamine, lead 
to modification of protein structure and functions thus contribute to the METH-induced DA 
terminal damages (LaVoie and Hastings, 1999). 
METH-induced accumulation of dopamine is also associated with excessive nitric oxide 
(NO) production.  This is supported by the results from animal studies showing that METH 
induced dopamine terminal damage along with six-fold increase of striatal 3-nitrotyrosine (3-NT), 
a biomarker for NO (Zhu et al., 2009). METH-induced NO production is a contributing factor to 
oxidative stress and neuronal apoptosis. The increase production of NO is known to activate 
guanylyl cyclase and consequently increases the expression of cyclic guanosine monophosphate 
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(cGMP) in striatal neurons. METH-induced increase of cGMP is also correlated with the increased 
activation of caspase-3, a biomarker for mitochondrial death pathway. It has been demonstrated 
that METH administration increased cGMP and caspase-3 by six-fold simultaneously (Yarosh and 
Angulo, 2012). However, blocking the activity of neuronal nitric oxide synthase (nNOS), one of 
the enzymes synthesize NO, with the inhibitors were shown to protect from the toxic effects of 
METH in the striatum (Itzhak et al., 2000). In general, oxidative stress caused by METH-induced 
excessive dopamine release contribute to neuronal damages. 
1.2.4 METH-induced oxidative stress by altering endogenous antioxidant system 
 
Multiple studies support the hypothesis that METH increased free radical formation in the 
striatum and caused oxidative stress (Giovanni et al., 1995, Cadet and Brannock, 1998, Yamamoto 
and Zhu, 1998). To maintain the homeostasis, cells are equipped with antioxidants (Vitamin E and 
glutathione) and antioxidative enzymes such as glutathione peroxidase, superoxide dismutase and 
catalase. METH-induced ROS or RNS accumulation is potentially caused by altering the normal 
activity of the endogenous antioxidative system. Indeed, METH administration has been shown to 
reduce the levels of catalase and glutathione (Harold et al., 2000, Açikgöz et al., 2001, Gluck et 
al., 2001). In addition, METH also increased superoxide dismutase activity in the rat striatum 
(Açikgöz et al., 1998). These findings are consistent with the increased levels of oxidized 
glutathione and copper-zinc superoxide dismutase (SOD-1) observed in the brains of METH 
abusers who suffered from severe dopamine loss in the striatum, which suggests the compensatory 
responses to the oxidative stress (Mirecki et al., 2004).  
Endogenous antioxidative enzymes play a crucial role in regulating oxidative stress level. 
METH administration alters the normal activity of antioxidative enzymes (Huang et al., 2013). 
This disruption of the antioxidant system caused by METH-induced ROS accumulation further 
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damaging the cellular components including lipids, proteins, mitochondrial and nuclear DNA 
(Açikgöz et al., 1998, Jayanthi et al., 1998, LaVoie and Hastings, 1999, Jayanthi et al., 2004, 
Johnson et al., 2015). Therefore, there has been a plethora of studies conducted to investigate 
oxidative stress as a potential target for treating METH-induced neurotoxicity. For instance, one 
study showed that the overexpression of human SOD-1  in the transgenic mice ameliorated the 
METH-induced DAT reduction (Hirata et al., 1996).  In addition, pretreatment with the 
antioxidants such as, N-acetylcysteine amide, vitamins C and E proved to attenuate METH-
induced neurotoxicity (De Vito and Wagner, 1989, Zhang et al., 2012). In general, these results 
strongly suggest that METH-induced oxidative stress is critical to the neuronal damages. 
1.2.5 METH-induced oxidative stress results in lipid peroxidation 
 
METH-induced lipid peroxidation is associated with the initiation of ROS accumulation. 
Lipid peroxidation occurs when ROS attack the polyunsaturated fatty acids of the membrane 
(Ayala et al., 2014). This process initiates a self-propagating chain reaction and causing the 
destruction of the cellular membrane (Hogg and Kalyanaraman, 1999). Accumulated evidence 
indicates that oxygen-based free radical formation due to METH administration is involved in 
oxidation of lipid or lipid peroxidation (Açikgöz et al., 1998, Jayanthi et al., 1998, Gluck et al., 
2001, Fitzmaurice et al., 2006). In one animal study, the rats showed an increase of lipid 
peroxidation in the striatum after METH administration (Açikgöz et al., 1998). This is consistent 
with the observation of elevated levels of lipid peroxidation products, 4-hydroxynonenal and 
malondialdehyde found in the brains of human METH addicts (Fitzmaurice et al., 2006). In the 
attempt to identify mechanisms that underlie METH-induced alteration of antioxidant enzymes 
level have revealed that the overexpression of SOD-1 in the transgenic mice ameliorate METH-
induced lipid peroxidation in the striatum and frontal cortex (Jayanthi et al., 1998). In addition, in 
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vitro study shows that overexpression of glutathione peroxidase (GPx), hydrogen peroxide-
reducing enzyme, reduced METH-induced ROS production, lipid peroxidation and cell death 
(Hom et al., 1997). Together these findings support the hypothesis that METH-induced oxidative 
stress causes lipid peroxidation. 
1.2.6 METH-induced oxidative stress contribute to apoptosis through the regulation of Bcl-
2 family proteins 
 
METH-induced neuronal death has been observed in the animal experiments (Deng et al., 
2001, Zhu et al., 2006b, a). These cell death processes are resembling apoptosis (Cadet et al., 2005). 
The mechanisms of METH-induced neuronal apoptosis are obscure. It has been proposed that 
METH-induced neuronal apoptosis involved in activation of multiple death pathways (Cadet et al., 
2005).  One of the proposed apoptotic pathways is involved in mitochondrial cell death pathways 
(Stefanis, 2005). The mitochondria-dependent death pathways are mediated, in part, by the Bcl-2 
family proteins (Leist and Nicotera, 1998).  
Bcl-2 family proteins are apoptotic regulators that can be divided into anti-apoptotic and 
pro-apoptotic proteins.  The anti-apoptotic proteins such as Bcl-2, Bclw and Bcl-XL can enhance 
cell survival whereas BAX, BAK, BID and BAD are pro-apoptotic proteins that promotes cell 
death (Volkmann et al., 2014). METH-induced alteration of Bcl-2 family protein expression has 
been observed in animal studies, and it was found that METH promoted apoptosis through 
upregulation of pro-apoptotic genes BAX, BAK, BAD and BID and downregulation of anti-
apoptotic gene Bcl-2 family (Imam et al., 2001, JAYANTHI et al., 2001). 
Neuronal cell death is partly involved in increase of pro-apoptotic/anti-apoptotic protein 
ratio in favor of apoptosis  (JAYANTHI et al., 2001). This shift in the apoptotic proteins ratio is 
partly attributed to the increase of METH-induced oxidative stress level. In vitro study revealed 
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that ROS induce apoptosis by regulating the phosphorylation and ubiquitination of Bcl-2 family 
proteins and resulting in increase of pro-apoptotic protein levels (Li et al., 2004). Therefore, 
METH-induced ROS production is potentially involved in apoptotic protein regulation. Indeed, 
the study showing that increase of vitamin E and glutathione peroxidase levels attenuate METH-
induced ROS production, and prevent apoptosis (Hom et al., 1997, Wu et al., 2007). In addition, 
in vitro study showed that overexpression of anti-apoptotic gene in neuronal cell cultures has a 
protective effect against METH-induced apoptosis (Cadet et al., 1997). Together, these results 
supported that excessive ROS production contribute to METH-induced apoptosis. However, to 
understand the association of ROS production in Bcl-2 family protein regulation require further 
studies.   
1.2.7 Role of glial cells in METH-induced neurotoxicity 
 
 Microglia and astrocytes are the most abundant glial cells found in the brain. These cells 
play an important role in maintaining homeostasis of the central nervous system (CNS) by 
releasing and recycling neurotransmitters, neurotrophic factors, cytokines, chemokines and 
extracellular matrix factors (Vesce et al., 2001, Auld and Robitaille, 2003, Bohn, 2004, Fellin and 
Carmignoto, 2004). METH-induced neuronal damage in the striatum are often associated with 
overactivation of microglia and astrocytes (Lau et al., 2000, Kuhn et al., 2006). For example, one 
study demonstrated that METH increased glial fibrillary acidic protein (GFAP) level, a biomarker 
for astrocytic activation, in the striatum of rats (Pu and Vorhees, 1993).  Microglia are beneficial 
during the resting state to maintain homeostasis. However, when microglia are activated, their 
phenotypes can vary from detrimental to supportive (Luo and Chen, 2012). Although METH-
induced glial activations have been observed in various studies, but the actual roles of glial 
activations are unclear.  
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Several lines of evidence from in vitro and in vivo studies have suggested that neuronal 
injury is associated with microglial activation (LaVoie et al., 2004, Thomas et al., 2004, Sekine et 
al., 2008). Microglial activation is also observed in brains of human METH abusers (Sekine et al., 
2008). In the attempt to study the role of METH-induced microglial activation, LaVoie et al. found 
that microglial activation preceded METH-induced depletion of dopamine transporter and tyrosine 
hydroxylase. Therefore, it is believed that the activation of microglia might be a contributing factor 
to the neuropathology in the presence of METH (LaVoie et al., 2004). However, study of the drug 
minocycline that inhibiting the METH-induced microglial activation showed that inhibition of 
microglial activation did not prevent striatal dopaminergic neurotoxicity suggesting a more 
complicated mechanism of METH-induced microglial activation (Sriram et al., 2006). 
Albeit the uncertainty on the role of microglial activation played in METH-induced 
neurotoxicity, microglial activation has been studied in various disease models, which revealed 
that microglia release several neurotoxins that includes pro-inflammatory cytokines (Bi et al., 2005, 
Dheen et al., 2005, Balasubramaniam et al., 2009), NO (Moss and Bates, 2001, Liu et al., 2002) 
and ROS (Colton and Gilbert, 1987, Mao and Liu, 2008). On the other hand, there are also studies 
showing that activated microglia protect dopaminergic neurons (Sawada et al., 2007) and remove 
glutamate without evoking inflammatory mediators after traumatic injury (Shaked et al., 2005).  
Furthermore, the protective role of microglia is substantiated in the experiment showing that the 
transgenic mice with deficiency of microglia exacerbate ischemic injury in the brain (Lalancette-
Hébert et al., 2007). These results suggest that activated microglial cells can be both neurotrophic 
and neurotoxic to the neurons and it depends on the severity of disease.  
METH-induced neuroinflammation is associated with activation of astrocytes. METH-
induced astrogliosis is indicated by the increase of GFAP, a biomarker for astrocytes activation 
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(Pu and Vorhees, 1993, O'Callaghan and Miller, 1994, Cappon et al., 1997). Previously, our lab 
has demonstrated that METH increases GFAP level in the mice striatum and the peak of METH-
induced astrogliosis occurred three days after METH administration (Zhu et al., 2005). In an effort 
to study the role of astrocytes, it has been revealed that astrocytes secrete unknown factors that 
enhance cell survival after neuronal injury (Hailer et al., 2001). Astrocytes also display a variety 
of receptors including glutamate receptors (Glaum et al., 1990, Parpura et al., 1994, Nedergaard et 
al., 2002) and dopamine receptors (Khan et al., 2001, Reuss and Unsicker, 2001). Activation of 
these astrocytic receptors enhance the synthesis and secretion of substances that can potentially 
modulate the surrounding neurons (Li et al., 2004, van Zundert et al., 2004, Narita et al., 2008b). 
Therefore, METH-induced glial activation can be a potential target for preventing further neuronal 
damages. 
1.2.8 Role of cyclooxygenase-2 (COX-2) in METH-induced dopamine depletion 
 
Cyclooxygenase (COX) is an enzyme that is responsible for producing prostaglandins, the 
inflammatory mediator, from arachidonic acids. There are two major COX isozymes: COX-1 is 
constitutively expressed, whereas COX-2 is inducible (Smith et al., 2000). Although METH-
induced neuroinflammation is implicated by glial activations and increases pro-inflammatory 
cytokines and chemokines (Goncalves et al., 2010, Loftis et al., 2011), but the association between 
METH-induced neuroinflammation and dopamine terminal damage still remains to be established. 
Recently, there is evidence showing that METH increases COX-2, but not COX-1, suggesting that 
COX-2 might be involved in the METH-induced neurotoxicity (Northrop and Yamamoto, 2013).  
METH is known to increase the expression of COX-2, but the role of COX-2 in METH-
induced dopaminergic damage is not well understood. Several studies have been conducted to 
access the function of COX-2 in METH-induced neurotoxicity, but the actual role of COX-2 is 
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contradictory. For instance, COX-2 knock-out mice are resistant to METH-induced striatal 
dopamine depletion (Thomas and Kuhn, 2005). However, selective inhibition of COX-2 using 
pharmacological approach showed that the potentiation of METH-induced dopamine depletion in 
the striatum (Zhang et al., 2007). These results may be contradicting as regard to the role of COX-
2, but it opens up the possibility that COX-2 can be both beneficial and toxic during METH 
administration. 
1.2.9 Blood-brain barrier dysfunction as a result of METH exposure 
 
The function of the blood-brain barrier (BBB) is to support and maintain the 
microenvironment in the CNS. BBB prevents neurotoxic plasma proteins from entering to the CNS 
and it also assists in neural signaling (Abbott et al., 2010).  BBB is made up of neurovascular unit, 
which consist of CNS endothelial cells, neurons and non-neuronal cells including perivascular 
astrocyte, microglia, and pericytes (Abbott and Friedman, 2012). The association of these cells at 
the BBB are depicted in Figure 3. Endothelium is the major site of the barrier, where it displays a 
network of tight junction and regulated transcytosis that restrict the entry of polar solutes and large 
molecules such as peptides and protein (Turowski and Kenny, 2015).  
The barrier functions of endothelial cells are assisted by pericytes (Shimizu et al., 2008) 
and astrocytes (Wolburg et al., 2009). The luminal side of BBB endothelial cells serve as the first 
line of filtration. The abluminal side of endothelial cells surrounded by the pericytes. The study of 
BBB formation mechanisms indicate that pericytes are required in the early development of BBB 
formation (Daneman et al., 2010). Pericytes also involved in regulating the immune response by 
suppressing CNS endothelial cells function, therefore decreasing vascular permeability and 
immune infiltration (Armulik et al., 2011). Damage to the BBB-associated pericytes appear to 
exacerbate Alzheimer’s disease as shown in post-mortem analysis (Montagne et al., 2015), 
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suggesting the importance of pericytes to the BBB function. On the other hand, astrocytes also 
play an important role in the function of BBB as part of the neurovascular unit. The perivascular 
endfeet of astrocytes form a complex network surrounding the cerebral capillary coupling the 
neural activity to the blood flow (Petzold and Murthy, 2011). Astrocytic activity also support the 
function of tight junction and the transport properties of BBB (Abbott et al., 2010). 
Microglia are the macrophages found in the CNS performing essential tasks in the immune 
response and neuronal homeostasis. The function of microglial cells also contribute to the property 
of the BBB (Barakat and Redzic, 2016). Microglia actively communicate with other cells in the 
neurovascular unit and the interaction is achieved by paracrine signaling utilizing chemokines, 
growth factors and cytokines (Lai and Todd, 2006, Smith et al., 2012, Girard et al., 2013). By 
secretion of these signaling factors microglia can contribute to the immune response. For example, 
activation of microglia increases the secretion of cytokines, which increases the permeability of 
BBB and therefore, promoting the infiltration of peripheral cells (Denieffe et al., 2013). Although 
BBB serve as line of barrier regulating immune response and preventing neurotoxin from entering 
to the brain, but it does not stop METH from crossing.  
The high permeability of METH through BBB is due to its small size and lipophilic 
property. METH rapidly reaches the brain soon after the initial injection and the peak accumulation 
occur within one hour after initial exposure as demonstrated in rodents (Martins et al., 2011b). 
Several studies have demonstrated the breakdown of BBB and its associated neuronal damages 
caused by METH in rodents (Bowyer et al., 2007, Martins et al., 2011b, Urrutia et al., 2013). The 
mechanisms of BBB disruption are, in part, associated with oxidative stress and the alteration of 
brain temperature. For instance, both hypothermic (Kiyatkin and Sharma, 2009) and hyperthermic 
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(Moriyama et al., 1991) temperatures of the brain increase the permeability of the BBB, but the 
hyperthermic condition exerts higher impact to the damage.  
Oxidative stress has been associated with the BBB disruption in various neurodegenerative 
diseases. Therefore, METH-induced oxidative stress may also contribute to BBB disruption. 
Interestingly, it has been suggested that METH-induced excess accumulation of ROS and RNS 
may promote BBB disruption through the alterations of endothelial structures and functions 
(Northrop and Yamamoto, 2015). In fact, the association of METH-induced oxidative stress and 
BBB disruption has been substantiated by the study showing that METH decreases protein 
expression of tight junction components such as claudin-5 and occludins (Mahajan et al., 2008, 
Ramirez et al., 2009a), thus increase the permeability of BBB. METH-induced oxidative stress as 
a cause of BBB disruption is further substantiated in the study showing that antioxidant, Trolox, 
attenuate METH-induced BBB breakdown in mice (Ramirez et al., 2009a). In general, both 
METH-induced oxidative stress and hyperthermia contribute to the disruption of BBB, which 
results in further damage to the neurons. 
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Figure 3. The composition of BBB as a neurovascular unit. The endothelial cells are the first 
line of filtration containing tight junctions that prevent the passage of molecules and ions from 
passing through the space between the adjacent cells. Pericytes are situated on the abluminal side 
of the endothelium lining along the length of cerebral capillary. Both pericytes and endothelium 
are surrounded by the basement membrane forming the basal lamina 1 (BL1) and the extracellular 
matrix of astrocytic endfeet form another basement membrane layer, basal lamina 2 (BL2). The 
endfeet of astrocytes surround the cerebral capillary forming a network that maintain the 
homeostasis and regulate the induction of inflammatory factors for the BBB. The crossing of 
solutes through BBB are facilitated either by passive or active transport. The efflux transporters of 
endothelial cells further control the solutes permeability through BBB. The accumulation of 
METH in the brain suggest that METH may avoid the efflux transportation by endothelium. 
(Adapted from (Abbott et al., 2010)) 
 
1.3 Potential drug candidates for treating METH-induced neurotoxicity 
 
Although a plethora of studies have delineated the METH-induced neurotoxicity, but there 
is still no effective treatment for METH. Therefore, it is necessary to investigate potential drug 
candidates that can prevent or treat METH-induced neurotoxicity without being toxic themselves. 
Our laboratory has extensively studied neuropeptides that play a pivotal role in METH-induced 
neurotoxicity. Some of these neuropeptides include substance P (SP) signaling contribute to 
METH-induced neurotoxicity, while others such as somatostatin, neuropeptide Y (NPY) and 
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neurotensin protect against it. Through pharmacological approach, these neuropeptides signaling 
pathway can be blocked or amplified to prevent METH-induced neuronal injury. However, these 
pharmacological agents are usually involved with synthetic agonist or antagonist, which are often 
resulted in many side effects. Recently, our attention shifted to natural products, which can have 
less side effects. Green tea extract, EGCG, seems to be a potential candidate as EGCG has been 
shown to have some neuroprotective effects on several neurodegenerative diseases. 
1.3.1 Role of neuropeptide substance P in METH-induced neurotoxicity 
 
 Neuropeptides such as substance P (SP) are short polypeptides that serve as signaling 
molecules in the neurons to communicate with each other. Striatal SP is produced by medium 
spiny projection neurons, these neurons comprise more than 90% of neuronal populations in the 
striatum (Kawaguchi et al., 1995). SP has highest binding affinity for the neurokinin-1 receptor 
(NK-1R), a G-protein-coupled receptor, and these receptors are abundantly localized on 
cholinergic, Neuropeptide Y (NPY) and neuronal nitric oxide synthase (nNOS) interneurons in the 
striatum (Gerfen, 1991, Morello et al., 1997, Li et al., 2001). SP/NK-1R signaling has been 
associated with excitotoxic neurotransmission in the central nervous system (Liu et al., 1999a, Liu 
et al., 1999b). METH exposure has been shown to increase striatal SP synthesis and it may 
potentially participated in METH-induced neurodegeneration (Frankel et al., 2007). This is 
supported by the study showing that knockout mice that lack SP gene were resistant to kainate-
induced hippocampal cell loss (Liu et al., 1999a). Our laboratory has also demonstrated that 
inhibition of SP signaling by treating antagonist on the NK-1R abrogated METH-induced striatal 
neurotoxicity (Yu et al., 2002, Yu et al., 2004, Zhu et al., 2006a). 
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1.3.2 Neuropeptide Y (NPY), somatostatin and neurotensin as neuroprotective agents 
 
Conversely, neuropeptides NPY, somatostatin and neurotensin all play a protective role in 
METH-induced neurodegeneration. NPY is a 36 amino acids long neuropeptide that has five 
known G-protein-coupled receptors in mice (Kask et al., 2002). NPY is expressed abundantly 
throughout central nervous system. Its function is, in part, to modulate the release of 
neurotransmitters and neuropeptides, including suppression of glutamate release and stimulation 
of somatostatin release (Silva et al., 2005). It has been shown that NPY and its receptors are 
involved in pathologies of various neurodegenerative diseases including schizophrenia, Hunting’s 
disease and epilepsy (Furtinger et al., 2001, Wagner et al., 2016, Morosawa et al., 2017). There 
are number of studies indicate that NPY protect against METH-induced neurotoxicity through 
activation of its receptors. For example, utilizing NPY receptor agonist to amplify the activation 
afforded protection against METH-induced neuronal loss and accumulation of nitric oxide in the 
striatum (Yarosh and Angulo, 2012). Therefore, it is suggesting that NPY serve as potential 
neuroprotective agent in the central nervous system. 
Somatostatin signals through five subtypes of G-protein-coupled receptors: somatostatin 
receptor 1 through somatostatin receptor 5 (Wängberg et al., 1997). Somatostatin is also involved 
in regulating the release of several neurotransmitters, including glutamate and dopamine 
(Momiyama and Zaborszky, 2006). The protective effects of somatostatins on excitotoxic insults 
seems to be associated with its inhibitory influence on glutamatergic release and transmission 
(Forloni et al., 1997). Our laboratory has demonstrated that somatostatin analogue octreotide 
pretreatment ameliorated METH-induced cell death but failed to protect dopamine terminal 
damages (Afanador et al., 2013), suggesting that somatostatin is partially participated in protecting 
against METH-induced neuronal damages.  
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Neurotensin is a 13 amino acid neuropeptide and localized abundantly in nigrostriatal and 
mesolimbic dopamine system (Jennes et al., 1982, Leeman and Carraway, 1982). Its effects are 
mostly achieved through activation of two subtypes of G-protein-coupled receptors: neurotensin 
receptor 1 (NTR1) and neurotensin receptor 2 (NTR2) (Vincent et al., 1999). Among these two 
receptors, NTR1 is the major neurotensin receptor located in the striatum. Recently, our laboratory 
demonstrated that activation of neurotensin receptor 1 by the agonist mitigated METH-induced 
apoptosis in the mouse striatum (Liu et al., 2017). In general, NPY, somatostatin and neurotensin 
all appear to protect against METH-induced neurotoxicity while substance P play a neurotoxic role 
during METH exposure. 
1.3.3 Epigallocatechin gallate: as a candidate of neuroprotective agent  
 
Recently, our laboratory found that Epigallocatechin gallate (EGCG) from green tea extract 
possesses neuroprotective properties that can potentially protect against the METH-induced 
neurotoxicity. In our studies, we have shown that EGCG prevented METH-induced neuronal 
apoptosis and tyrosine hydroxylase reduction (Liu et al., 2014). However, the mechanisms 
involved in METH-induced neuroprotection is still unclear. In this study, we will further 
investigate the efficacy of EGCG and the potential mechanisms involved in preventing METH-
induced neurotoxicity. 
1.3.3.1 Efficacy of green tea catechins in neurodegeneration 
 
Tea is the second most frequently consumed beverage worldwide. It is believed that tea-
drinking can promote health and reduce the risk of brain aging, dementia and neurodegeneration. 
In fact, the modern medicinal research has supported this belief with the data published in scientific 
literature. In the previous epidemiological study, it has shown that drinking 2 cups/day or more of 
21 
 
tea reduced the risk of Parkinson’s disease (Checkoway et al., 2002). In another cross-sectional 
study, it was found that the higher consumption of green tea is associated with lower prevalence 
of cognitive impairment among the 1,003 Japanese subjects (Kuriyama et al., 2006). The health-
promoting properties of tea consumption are believed to be associated with the bioactive 
compound catechins, which act as antioxidant and anti-inflammatory agents (Higdon and Frei, 
2003, Mandel et al., 2005, Weinreb et al., 2009). 
 Catechins are polyphenolic flavonoid-type compounds, which is made up of 25-35% of the 
green tea extract (Weinreb et al., 2009). EGCG is the most abundant catechin found in green tea, 
and every 2.5 grams of green tea leaves may contain about 90 mg of EGCG (Wu and Wei, 2002, 
Lin et al., 2003). In order to exert its neuroprotective effects in the brain, EGCG requires to enter 
the systematic circulation and permeate through BBB. Interestingly,  EGCG has been found in the 
plasma and the maximal plasma concentration can be reached at about 2 hours after oral 
administration (Nakagawa and Miyazawa, 1997). EGCG is mainly excreted through urine and bile 
(Cabrera et al., 2006). The complete excretion of EGCG occur within 24 hours (Lee et al., 2002) 
and the half-life of EGCG is about 5 hours (Yang et al., 2000, Yang et al., 2003). Although EGCG 
enters the body through tea drinking, but the question is whether it is sufficient to exert its effect 
in the brain. In fact, the level of EGCG is higher in esophagus and large intestine than in small 
intestine (Cabrera et al., 2006), which may affect the systemic absorption of EGCG and limit its 
bioavailability (Gawande et al., 2008). Nevertheless, EGCG was found in the brain of adult and 
fetal rats after oral or intravenous administration (Chu et al., 2007), which supports that EGCG 
permeate through BBB. In addition, various studies have indicated that tea polyphenols exert its 
neuroprotective effects in the brain through tea drinking (Levites et al., 2001, Rezai-Zadeh et al., 
2008), suggesting that EGCG has the potent effect even with limited amount.  
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1.3.3.2 Neuroprotective mechanisms of EGCG on METH-induced neurotoxicity 
 
It is known that catechins act as biological antioxidants to scavenge free radicals (Nanjo et 
al., 1996, Nanjo et al., 1999, Forester and Lambert, 2011). Catechins also chelate metal ions to 
prevent free radical formation (Seeram et al., 2006). A large number of studies have indicated that 
EGCG is more efficient in radical scavenging than all of the other catechins found in green tea, 
this may be associated with the presence of trihydroxyl group on the B ring and the galloyl group 
at the 3’ position in the C ring (Figure 4) (Nanjo et al., 1996, Guo et al., 1999, Nanjo et al., 1999). 
It has been suggested that the neuroprotective effects of EGCG in the brain is attributed to its 
ability to regulate levels of metal ions (Weinreb et al., 2009). Iron accumulations are typically 
found in the brain regions of neurodegenerative diseases, such as Parkinson’s disease (Riederer et 
al., 1989). Interestingly, METH also increases iron level in the brains of vervet monkeys (Melega 
et al., 2007). Thus EGCG can be a potential drug candidate for treating METH-induced 
neurotoxicity. In particular EGCG is a potent metal chelators (Guo et al., 1996, Grinberg et al., 
1997), but it does not interfere with iron absorption in healthy human (Cheng, 2009).  
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Figure 4. Four derivatives of catechins found in green tea. The schematic diagram shows the 
comparison of chemical structure between EGCG and other catechins epicatechin (EC), 
epicatechin gallate (ECG), and epigallocatechin (EGC). EGCG has been reported to be more 
efficient in free radical scavenging. EGCG contains both tri-hydroxyl group and a galloyl group 
(in circles), which may contribute to the strong antioxidative property.  
 
Neuroprotective property of EGCG on METH-induced neurotoxicity has not been 
investigated extensively, but the protective effects of EGCG on neurodegenerative diseases, such 
as Parkinson’s disease and Alzheimer’s disease, has been studied to some extent. For instance, 
EGCG has been shown to prevent mice striatal dopamine depletion and substantia nigra 
dopaminergic neuronal damage caused by neurotoxin N-methyl-4-phenyl-1,2,3,6-
tetrahydrophyridine (MPTP), which was used as Parkinson’s disease model (Levites et al., 2001). 
The potent effect of EGCG is further demonstrated in Alzheimer’s disease. The study of 
Alzheimer’s disease using transgenic mice model, which overexpressed amyloid precursor protein 
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(APP), has shown that EGCG is effective in reducing beta-amyloid and plagues through promotion 
of the non-amyloidogenic alpha-secretase proteolytic pathway (Rezai-Zadeh et al., 2005, Rezai-
Zadeh et al., 2008). Together, these studies of EGCG on neurodegenerative diseases indicate that 
EGCG may not just limited to simple iron chelating and free radical scavenging. 
Recently, our laboratory has provided the biochemical observation showing that EGCG 
ameliorate METH-induced neurotoxicity via prevention of METH-induced apoptosis and 
dopamine terminal damage in mice striatum (Liu et al., 2014). These results along with the studies 
of EGCG on other neurodegenerative diseases (Choi et al., 2001, Levites et al., 2001, Rezai-Zadeh 
et al., 2005, Rezai-Zadeh et al., 2008) indicate that EGCG might have potent effect in protecting 
against neurodegenerative diseases as well as METH-induced neurotoxicity. In this research, we 
aim to elucidate the potent effects of EGCG on METH-induced neuronal damages by investigating 
the oxidative stress and neuroinflammation, which is significant for the potential drug development. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Animals 
 
CD-1 male mice were purchased from Charles River Breeding Laboratories (Wilmington, 
MA, USA) at 10 weeks of age.  All mice were housed individually in a temperature-controlled 
environment on a 12 hr light/dark cycle with food and water provide ad libitum.  All mice were 
habituated for 1 week prior to commencement of intraperitoneal (ip) drug administration. All 
procedures involving animal use were performed in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee of Hunter College, City University of New York. In addition, all 
efforts were made to minimize the number of animals used and their suffering.  
2.2 Drug preparation and treatment 
 
(+)-Methamphetamine hydrochloride (METH) and (-)-Epigallocatechin gallate (EGCG) 
were purchased from Sigma Aldrich (St. Louis, MO, USA). EGCG (2 mg/kg) or METH (30 mg/kg) 
was diluted in 0.9% sodium chloride and administered to the animals intraperitoneally. All 
injections followed the same regimen unless specified, EGCG (2mg/kg, ip) was administered to 
the animals 30 minutes prior to the METH (30 mg/kg, ip) injection and the detail drug treatment 
is depicted in Figure 5.  
2.3 Tissue preparation 
 
The animals were sacrificed by decapitation under anesthesia by isoflurane at 8 hr, 24 hr 
or three days after METH administration. Striatal tissues were dissected from the brains between 
bregma 0.14 and 1.54mm, and the tissues were washed in cold PBS and dried between filter papers. 
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The samples were weighed and placed on dry ice. Then the tissues were either immediately 
homogenized in cold RIPA buffer for Western blot analysis or stored at -80 °C until use. 
2.4 Determination of GPx activity 
 
Striatal GPx activities were determined by the commercial kit (Abcam 102530, Cambridge, 
MA) per manufacturer’s instructions. In brief, 50 µl of protein sample was mixed and incubated 
with 33 µl assay buffer, 3 µl of NADPH, 2 µl of glutathione reductase, and 2 µl of glutathione at 
room temperature for 15 minutes. Then the reaction was initiated by adding 10 µl of cumene 
hydroperoxide. The absorbance was measured at 340 nm by PowerWave HT Microplate 
Spectrometer (BioTek) every 5 minutes for 20 minutes. The rate of decrease in NADPH is 
proportional to GPx activity. Results are expressed as change of nmol of NADPH per minute per 
mg of protein (nmol/min/mg).  
2.5 Western blot analysis 
 
Striatal tissues were homogenized by sonication in 300 µl of cold RIPA buffer. The 
supernatants were collected after centrifuged at 12,000 rpm at 4°C for 20 minutes. The protein 
concentrations were determined by Pierce BCA Protein Assay Kit (Thermo Fischer, Rochford, IL). 
Twenty micrograms of each protein sample was boiled at 95 °C in loading buffer for 5 minutes 
and were resolved by molecular weight in 12.5% of Tris-HCl SDS-PAGE (Bio-Rad, Hercules, CA, 
USA). After the samples were transferred to a PVDF membrane by iBLot transfer system 
(Invitrogen, Carlsbad, CA), the membranes were incubated in Odyssey blocking buffer for 1 hr at 
room temperature. Then the membranes were incubated with primary antibodies rabbit anti-GPx-
4 (1: 3,000, ab125066 abcam, Cambridge, MA) or rabbit anti-SOD-1 primary antibody (1:1,500, 
ab16831, abcam, Cambridge, MA) or rabbit anti-CAT primary antibody (1:1,500, ab209211, 
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abcam, Cambridge, MA) or rabbit anti-tyrosine hydroxylase (1:2,000) and mouse anti-β-actin 
primary antibody (1:7,500, Abcam, Cambridge, MA) in blocking buffer (Odyssey,) with 0.1% 
Tween-20 at 4°C overnight. Next day the membranes were washed with 0.1% Tween-20 in PBS 
followed by incubation in a mixture of secondary antibodies goat anti-rabbit 800CW (1:15,000, 
LI-COR, Lincoln, NE) and goat anti-mouse 680LT (1:20,000, LI-COR, Licoln, NE) in Odyssey 
blocking buffer with 0.1% Tween-20 and 0.01% SDS at room temperature for 1 hr. After the 
incubation, the membranes were washed with 0.1% Tween-20 in PBS and then washed with PBS. 
After the final wash with PBS, the membranes were analyzed by Odyssey infrared imager (LI-
COR, Lincoln, NE). Bands were quantified by Odyssey Imager analysis software and normalized 
by β-actin as an internal control. 
2.6 Core body temperature measurement 
 
Core body temperature of mice were measured by BAT-12 thermometer coupled with 
RET-3 mouse rectal probe (Physitemp Instruments, Clifton, NJ, USA). Ambient room temperature 
was maintained at 20-22 °C. 
2.7 Detection of astrocytic activation: GFAP immunohistochemistry  
 
One day or three days after second injection (METH or saline), mice were perfused and 
dissected as described above. Tissue sections of 30 μm were then stored at -20°C in cryoprotectant 
(0.05 M PBS with 30% glycerol and 30% ethylene glycol) solution until use. Five sections were 
randomly selected from one well of each six adjacent wells. Coronal sections were then washed 
with PBS and incubated in goat anti-GFAP primary antibody (1:400, abcam; Cambridge, MA) 
with PBS and 0.3% Triton X-100 overnight at 4°C. After washing with PBS in the next day, the 
sections were incubated with secondary antibody chicken anti-goat (Alexa Fluor 594, 1:500, 
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Invitrogen; Carlsbad, CA) in PBS with 0.3 % Triton X-100 at room temperature for 90 minutes. 
Then the sections were washed with PBS, mounted with Hardset Vectashield with DAPI mounting 
medium H1500 and sealed the sections with coverslips. All images were obtained from both 
hemispheres of each coronal section using epifluorescence microscope with TRITC filter (Nikon 
Eclipse TE 200 Calcium Ratio and Micro Injection). 
2.8 Detection of microglial activation: Iba-1 immunohistochemistry 
 
Same coronal sections of the striatum were obtained as described in GFAP 
immunohistochemistry. All sections were then washed with PBS followed by blocking in 5% 
Donkey serum for 30 minutes. After blocking, all sections were incubated in anti Iba-1 primary 
antibody (rabbit polyclonal, 1:400, Wako 019-19741; Richmond, VA) overnight at 4°C. After PBS 
wash in the next day, the sections were incubated in donkey anti-rabbit secondary antibody (1:500, 
Invitrogen A21206; Temecula, CA) in PBS with 0.3 % Triton X-100 at room temperature for 2 
hours. Then the sections were washed and mounted with Vectashield mounting medium H1500 
and sealed with coverslips. All images were obtained from both hemispheres of each coronal 
section using epifluorescence microscope with FITC filter (Nikon Eclipse TE 200 Calcium Ratio 
and Micro Injection). 
2.9 Detection of striatal COX-2 using immunohistochemistry 
 
Coronal sections from one or three days after the second injection (METH or saline) were 
preserved and obtained in the same way as described in GFAP immunohistochemistry. Briefly, 
five sections were randomly selected from one well of each six adjacent wells. Coronal sections 
were then washed with PBS and incubated in rabbit anti-COX-2 primary antibody (1:50, 
Invitrogen MA5-14568; Cambridge, MA) with PBS and 0.3% Triton X-100 overnight at 4°C. Next 
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day the sections were washed with PBS and the sections were incubated with secondary antibody 
donkey anti-rabbit (1:800, Invitrogen A21206, Cambridge, MA) in PBS with 0.3 % Triton X-100 
at room temperature for 2 hours. Then the sections were washed with PBS, mounted with Hardset 
Vectashield with DAPI mounting medium H1500 and covered with coverslips. All images were 
obtained from both hemispheres of each coronal section using epifluorescence microscope with 
FITC filter (Nikon Eclipse TE 200 Calcium Ratio and Micro Injection). 
2.10 FITC-dextran extravasation 
 
The leakage of FITC-dextran (MW= 10 KD, Sigma, St. Louis, MO) from vasculature into 
brain parenchyma was tested to determine BBB integrity. The protocol similar to (Northrop and 
Yamamoto, 2012) and (Zhao et al., 2007) was used. Briefly, 24 hr or 3 days after following last 
METH or saline injections, the mice were anesthetized with ketamine (100 mg/kg) and 
acepromazine (3 mg/kg). Heparin (100 units/kg in Hank’s Balanced Salt Solution) was injected 
through left ventricle followed by 10 mL FITC-dextran perfused at a rate of 5 ml/minute with right 
atrium snipped. Then the brains were removed immediately and transferred into 4% 
paraformaldehyde at 4°C with constant agitation for three days. After that, the brains were 
transferred to 30% sucrose until impregnated. Then the brains were sliced with thickness of 40 µm 
using a cryostat and divided into 6 consecutive free-floating series in cryoprotectant (0.05 M PBS 
with 30% glycerol and 30% ethylene glycol). All images were obtained from both hemispheres of 
each coronal section using epifluorescence microscope with FITC filter (Nikon Eclipse TE 200 
Calcium Ratio and Micro Injection). 
The quantification of FITC-dextran extravasation of mice brain is based on the method 
described by Northop and Yamamoto’s group (2012). Briefly, the brightly stained brain capillaries 
in each image were removed by setting the parameters of threshold and radius in ImageJ software. 
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Threshold and radius settings were chosen based on the settings that removed capillary staining 
from the control (saline-treated group) slice images and used the same settings for all the other 
groups. The average intensity of the remaining fluorescence of the entire area was quantified by 
ImageJ. The fluorescence values of the 8 images, take from 4 slices from each mouse, were 
averaged for each individual mouse. The mean intensity of fluorescence was expressed as a percent 
of control and is indicative of FITC-dextran extravasation. 
2.11 Statistical analysis 
 
All the data were analyzed by GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) 
statistical analysis software. Data comparison between the four groups were conducted by one-
way ANOVA mean ± SEM followed by Tukey’s honest significance test. The significance was 
set at p ≤ 0.05. The null-hypothesis, indicating no significant different between groups, was 
rejected when the p-value was less than 0.05. 
 
Figure 5. Timeline for injection and sacrificing of mice. CD-1 male mice were injected with 2 
mg/kg of EGCG or equivalent volume of saline 30 minutes prior to the injection of 30 mg/kg of 
METH or equivalent volume of saline. Then the core body temperature of mice were measured 
every hour for total of six hours after the second injection. The mice were sacrifice at 8 hr, 24 hr 
or 3 days after the injection. The brains of mice were extracted and stored for further analysis. 
31 
 
CHAPTER 3. RESULTS 
 
3.1 Determine whether EGCG prevents the METH-induced dopamine terminal damage in 
CD-1 mice 
 
Tyrosine hydroxylase (TH) is the rate-limiting step for generating dopamine and METH 
exposure is known to cause TH protein reduction, therefore it is a reliable marker of the METH-
induced dopaminergic neurotoxicity. In order to evaluate whether EGCG has protective effects 
against the METH-induced neurotoxicity in CD-1 mice, striatal TH protein levels were measured 
three days after METH (30 mg/kg, ip) or saline injection. We observed that striatal TH protein 
levels were reduced by 50% three days after the METH injection compared to saline-treated group 
by Tukey comparison test (p < 0.0001), indicating that METH induced dopaminergic neuronal 
toxicity (Figure 6). Strikingly, CD-1 mice pretreated with EGCG (2 mg/kg, ip) 30 minutes prior 
to the METH (30 mg/kg, ip) injection showed higher striatal TH protein levels than the group that 
received METH alone (p < 0.005), with TH protein levels comparable to saline-treated control 
group (Figure 6). Injection of EGCG alone did not alter TH protein levels. One-way ANOVA 
shows that these differences between groups were significant [F(3,33) = 13.32, p < 0.0001].  
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Figure 6. EGCG prevented the METH-induced reduction of striatal tyrosine hydroxylase 
(TH) protein levels in CD-1 mice three days after the second injection. Administration of 
METH (30 mg/kg, ip) induced a decrease of TH protein levels three days after the injection and 
pretreatment with EGCG (2 mg/kg, ip) 30 minutes prior to the METH injection prevented this 
decrease. Data represent mean ± SEM values; all data were analyzed by one-way ANOVA 
followed by Tukey’s multiple comparisons test (n ≥ 8). Protein loading in each well was 
normalized by β-actin and then normalized to the mean of controls (saline group). **p < 0.005 
compared to METH-treated group, #### p < 0.0001 compared to Saline-treated group. 
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3.2 EGCG did not prevent the METH-induced hyperthermia in CD-1 mice 
 
METH administration is known to induce hyperthermia, which is also a leading cause of 
METH-induced neuronal damage. To test whether EGCG suppresses the METH-induced 
hyperthermia, CD-1 mice (n=7-9 per group) were injected with EGCG 30 minutes prior to METH 
or saline injection and we measured the core body temperature of the mice every hour for six hours 
after METH or saline injections. METH increased core body temperature to 40°C and peaked 
between 30 minutes and 1 hr after METH injection as indicated by red green (Figure 7). The core 
body temperature of METH-treated group between 30 minutes and 1 hr after the injections was 
significantly higher than saline-treated group as shown in blue line (p < 0.005) (Figure 7). 
Pretreatment of EGCG 30 minutes prior to METH failed to abrogate the METH-induced 
hyperthermia as shown in red line (Figure 7). Injection of EGCG alone did not induce hyperthermia 
as indicated by orange line (Figure 7). 
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Figure 7. EGCG did not prevent the METH-induced hyperthermia in CD-1 mice. Core body 
temperature was recorded for the first 6 hr after METH injection. Injection of METH (30 mg/kg, 
ip) to CD-1 mice induced hyperthermia within 1 hr after METH injection. Pretreatment of EGCG 
(2 mg/kg, ip) 30 minutes prior to METH injection did not prevent hyperthermia. Data represent 
mean ± SEM values; all data were analyzed by one-way ANOVA followed by Tukey’s multiple 
comparisons test (n ≥ 7). **p < 0.005 EGCG+METH-treated group compared to saline-treated 
group. ####p ≤ 0.0001 METH-treated group compared to saline-treated group at 1 hr after METH 
injection. 
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3.3 EGCG prevented the METH-induced reduction of striatal glutathione peroxidase 
(GPx) activity  
 
GPx is the endogenous enzyme that converts hydrogen peroxide to water with the 
consumption of reduced glutathione. As METH is known to increase oxidative stress, the 
endogenous antioxidative enzymes are also dysregulated. To evaluate the hypothesis that the 
neuroprotective properties of EGCG are attributed to its ability to attenuate oxidative stress, we 
measured the striatal GPx activity by colorimetric method at 8 hr and 24 hr after METH injection. 
The results indicated that METH caused alteration of GPx activity at 8 hr after the injection (Figure 
8A). At 24 hr, Tukey comparison test showed that METH significantly reduced GPx activity by 
40% compared to saline-treated group (p < 0.001) (Figure 8B). However, CD-1 mice pretreated 
with EGCG (2 mg/kg, ip) 30 minutes prior to METH (30 mg/kg, ip) injection showed significantly 
higher striatal GPx activity than the METH-treated group, but were similar to saline-treated group 
at 24 hr after METH injection (p < 0.0001) (Figure 8B). Administration of EGCG alone had no 
effect on striatal GPx activity. One-way ANOVA indicated that these differences between groups 
are significant [F(3,28) = 11.43, p < 0.0001].  
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Figure 8. EGCG pretreatment prevented the METH-induced reduction of glutathione 
peroxidase (GPx) activity. (A) METH did not alter GPx activity in the striatum at 8 hr, (B) but 
significantly decreased GPx activity at 24 hr. (B) Pretreatment with EGCG (2 mg/kg, ip) 30 
minutes prior to METH (30 mg/kg, ip) injection prevented this reduction. One unit of GPx is 
defined as 1 nmol of NADPH consumed per minute per milligram protein. Data represent mean ± 
SEM values; all data were analyzed by one-way ANOVA followed by Tukey’s multiple 
comparisons test (n ≥ 7). ****p < 0.0001 EGCG + METH-treated group compared to METH-
treated group. ##p < 0.001 METH-treated group compared to saline-treated group. 
 
 
 
 
 
37 
 
3.4 METH reduced GPx-4 protein levels and this reduction was prevented by EGCG  
 
GPx-4 is one of the isozymes of GPx. It catalyzes the conversion of hydrogen peroxide 
into water and it protects the membrane from lipid peroxidation. To further determine whether the 
METH-induced reduction of GPx activity resulted from dysregulation of GPx protein levels, 
striatal GPx-4 protein levels were measured by Western blotting. We observed no significant 
change among all four groups at 8 hr after METH or saline injection, striatal GPx-4 protein levels 
of METH, EGCG+METH, and EGCG-treated groups were comparable with the saline-treated 
group (Figure 9A). However, striatal GPx-4 protein levels of the METH-treated group were 
significantly reduced at 24 hr after the METH injection compared to saline-treated group (p < 
0.001) (Figure 9B). At 24 hr, pretreatment with EGCG (2 mg/kg, ip) 30 minutes prior to METH 
(30 mg/kg, ip) injection prevented the METH-induced decrease of GPx-4 protein levels (p < 0.001) 
(Figure 9B). Injection of EGCG alone did not alter the striatal GPx-4 protein levels. One-way 
ANOVA showed that the differences between groups at 24 hr are significant [F(3,39) = 8.462, p 
= 0.0002].   
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Figure 9. EGCG pretreatment prevented the METH-induced reduction of glutathione 
peroxidase 4 (GPx-4) protein level in the striatum.  (A) Western blot analysis showed that 
METH did not alter GPx-4 protein level at 8 hr post-METH injection. (B) However, METH 
significantly reduced GPx-4 protein level at 24 hr and it was prevented by EGCG pretreatment. 
Data represent mean ± SEM values; all data were analyzed by one-way ANOVA followed by 
Tukey’s multiple comparisons test (n ≥ 7). Protein loading in each well was normalized by β-actin 
and then normalized to the mean of controls (saline group). ***p < 0.001 EGCG + METH-treated 
group compared to METH-treated group. ###p < 0.001 METH-treated group compared to saline-
treated group. 
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3.5 EGCG prevented the METH-induced increase of CAT protein levels  
 
To further study the mechanisms by which EGCG protects against the METH-induced 
oxidative stress, the striatal CAT protein levels were measured by Western blot at 8 hr and 24 hr 
after METH injection (Figure 10A and B). As shown in Figure 10A, administration of METH 
caused no alteration of striatal CAT protein levels 8 hr after METH or saline injection. However, 
METH significantly increased striatal CAT protein levels by 30% (p < 0.05) 24 hr after the 
injection as compared to saline-treated group (Figure 10B). We also observed that EGCG 
pretreatment prevented the METH-induced increase of CAT protein levels at 24 hr after METH 
injection. This is demonstrated by the Tukey’s test indicating that the injection of EGCG (2 mg/kg, 
ip) 30 minutes prior to METH (30 mg/kg, ip) administration significantly lowered CAT protein 
levels by 34% compared to METH-treated group (p < 0.005), but showed no significant difference 
as compared to saline-treated group, suggesting that EGCG was effective in suppressing METH-
induced oxidative stress (Figure 10B). Injection of EGCG alone did not alter CAT protein levels 
as comparable to saline-treated group at both 8 hr and 24 hr after METH injection. One-way 
ANOVA showed that the effect of EGCG in preventing METH-induced alteration of CAT protein 
levels at 24 hr is significant [F(3,21)=7.109, p=0.0018]. 
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Figure 10. EGCG prevented the METH-induced increase of catalase (CAT) protein level. (A) 
METH did not affect striatal CAT protein level at 8 hr, (B) but significantly increased CAT protein 
level at 24 hr after METH (30 mg/kg, ip) injection. (B) Pretreatment with EGCG (2 mg/kg, ip) 30 
minutes prior to the METH administration prevented the METH-induced increase of CAT protein 
levels. Data represent mean ± SEM values; all data were analyzed by one-way ANOVA followed 
by Tukey’s multiple comparisons test (n ≥ 7). Protein loading in each well was normalized by β-
actin and then normalized to the mean of controls (saline group). **p < 0.005 EGCG + METH-
treated group compared to METH-treated group, #p < 0.05 METH-treated group compared to 
saline-treated group. 
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3.6 EGCG protected against the METH-induced increase of Copper/Zinc superoxide 
dismutase (SOD-1) protein levels 
 
SOD-1 is one of the endogenous antioxidative enzymes, involved in the conversion of 
superoxide to hydrogen peroxide thus reducing oxidative stress. To further confirm whether EGCG 
prevented the METH-induced oxidative stress, SOD-1 protein levels were quantified by Western 
blot. Tukey’s multiple comparison showed that striatal SOD-1 protein levels in the METH-treated 
group were significantly increased 8 hr after METH injection compared to saline-treated group (p 
< 0.05) (Figure 11A). Conversely, striatal SOD-1 protein levels in EGCG+METH-treated group, 
where mice pretreated with EGCG (2 mg/kg, ip) 30 minutes prior to METH (30 mg/kg ip), were 
comparable to the saline-treated control group (p < 0.05) (Figure 11A). At 24 hr after the METH 
injection, METH-treated group showed higher striatal SOD-1 protein levels than the other three 
groups but it did not approach statistical significance (Figure 11B). EGCG alone did not affect 
striatal SOD-1 protein levels as compared to saline-treated group at both 8 hr and 24 hr after the 
saline injection. One-way ANOVA confirmed that the prevention of METH-induced increase of 
striatal SOD-1 protein levels by EGCG at 8 hr is significant [F(3,23)=4.043, p=0.0191], but not at 
24 hr after the METH injection. 
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Figure 11. EGCG prevented the METH-induced increase of striatal copper/zinc superoxide 
dismutase (SOD-1) protein level. (A) Administration of METH increased SOD-1 protein level 
at 8 hr and was prevented by EGCG pretreatment. (B) SOD-1 protein level started to decrease at 
24 hr after METH administration, although it is still higher than saline-treated group but it is not 
statistically relevant. Data represent mean ± SEM values; all data were analyzed by one-way 
ANOVA followed by Tukey’s multiple comparisons test (n ≥ 7). Protein loading in each well was 
normalized by β-actin and then normalized to the mean of controls (saline group). *p < 0.05 EGCG 
+ METH-treated group compared to METH-treated group, #p < 0.05 METH-treated group 
compared to saline-treated group. 
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3.7 EGCG potentiated the METH-induced microglial activation 
 
 Microglial cells are macrophages found in the central nervous system. These cells are 
responsible for the immune response in the brain. However, chronic activation of microglial cells 
can change them into a phagocytic state that can engulf damaged neuronal cell fragments. 
Therefore, it has been suggested that the METH-induced microglial activation is contributing to 
neuronal injury. In this study, we aim to elucidate the effect of EGCG on the METH-induced 
microglial activation. 
To measure the effect of EGCG on the METH-induced microglial activation, the microglial 
cells were labeled with the biomarker ionized calcium-binding adapter molecule 1 (Iba-1) 1 day 
and 3 days after injection of METH or saline. The images of striatal Iba-1 labeled cells were taken 
by epifluorescence microscopy. The results showed that a single high dose (30 mg/kg, ip) of 
METH significantly increased Iba-1-FITC fluorescence signal up to 208% as comparing to the 
saline-treated control group 1 day after the METH injection (p < 0.0001), which is shown by 
brighter green FITC fluorescence on the METH-treated group compared to saline-treated group 
(Figure 12A and B). Unexpectedly, pretreatment of EGCG 30 minutes before METH injection 
potentiated METH-induced microglial activation as indicated by the increase of Iba-1-FITC 
fluorescence signal up to 273% comparing to saline-treated group (p < 0.0001) and it is about 68% 
more than METH-treated group ((p < 0.0001 )(Figure 12A and B). Injection of EGCG alone did 
not induce microglial activation as shown in Figure 12. Three days after METH administration 
microglial activation level in both METH-treated group and EGCG+METH-treated groups were 
reduced to the basal level (saline-treated group) as indicated by no significant changes of Iba-1 
signal (Figure 12B). Two-way ANOVA confirms that EGCG potentiated METH-induced 
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microglial activation on day one after METH injection is significant [F(3, 376) = 71.66, p < 
0.0001]. 
A
 
 
 
B 
 
Figure 12. EGCG potentiated the METH-induced microglial activation. (A) METH injection 
increased microglial activation 1 day after its exposure as indicated by enhanced Iba-1-FITC 
intensity as in green color, and the pretreatment of EGCG potentiated METH-induced microglial 
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activation as shown under EGCG + METH group. Three days after the injection there is no 
significant changes across the groups. (B) Quantification of Iba-1 shows that METH-treated group 
increased Iba-1-FITC fluorescence to 209% of the control 1 day after METH exposure, while 
EGCG-METH-treated group increased to 277% of the control, which is 68% more than METH-
treated group. There are no significant changes among the groups 3 days after the injection. Data 
represent mean ± SEM values; all data were analyzed by Two-way ANOVA followed by Tukey’s 
multiple comparisons test (n ≥ 7). Iba-1-FITC fluorescence among all groups are normalized to 
the mean of control (saline group). ****p < 0.0001 EGCG + METH-treated group compared to 
METH-treated group on day 1 after METH exposure. 
 
3.8 EGCG potentiated the METH-induced astrocytic activation 
 
To further investigate the effect of EGCG on the METH-induced neuroinflammation, we 
quantified astrocytic activation utilizing immunohistochemistry and Western blotting with the 
biomarker glial fibrillary acid protein (GFAP) to label the astrocytes. Epifluorescence images of 
striatal GFAP expression on day 1 and day 3 after injection of METH or saline are shown in Figure 
13A. The results show that striatal astrocytic activation levels in METH-treated group were 
significantly increased 1 day after METH injection as indicated by GFAP-TRITC green 
fluorescence (Figure 13A), and the quantification of striatal  GFAP-TRITC fluorescence shows 
that GFAP in METH-treated group increased up to about 194% of saline-treated group (p = 0.0002) 
(Figure 13B). Similarly, EGCG pretreatment in EGCG+METH-treated group also increased 
striatal GFAP level up to 198% of saline-treated group 1 day after METH injection (p < 0.0001)  
(Figure 13A). There is no significant difference in striatal GFAP level between METH-treated 
group and EGCG+METH-treated group on day 1 after the METH injection. Three days after 
METH injection striatal GFAP-TRITC level potentiated in METH-treated group as compared to 
day 1 (Figure 13A), and the quantification of striatal GFAP-TRITC shows that METH 
significantly increased GFAP level by 304% of saline-treated group (p < 0.0001)  (Figure 13B). 
Interestingly, the pretreatment of EGCG in EGCG+METH-treated group also increased striatal 
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GFAP level, but the level of striatal GFAP is significantly higher than the METH-treated group 
up to 417% of saline-treated group (p < 0.0001) and 113% more than METH-treated group (p < 
0.0001) (Figure 13B).  
The potentiation of METH-induced astrocytic activation by EGCG 3 days after METH 
injection is further confirmed by Western blot. The quantification of striatal GFAP protein level 
shows that the METH-treated group is 193% of saline-treated group (p = 0.0016) (Figure 14). 
EGCG+METH-treated group has GFAP protein level up to 260% of saline-treated group in the 
striatum (p < 0.0001), that is significantly higher than METH-treated group (p < 0.05) (Figure 14). 
Injection of saline or EGCG alone did not show significant change of striatal GFAP protein level, 
suggesting that EGCG promoted METH-induced astrocytic activation. Two-way ANOVA 
confirmed that EGCG significantly potentiated METH-induced striatal astrocytes activation on 
day 3 after METH injections [F(3, 53) = 28.58, p < 0.0001]. 
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A 
 
B 
 
Figure 13. EGCG potentiated the METH-induced astrocytic activation. (A) METH increased 
astrocytic activation 1 day after METH injection as indicated by red fluorescence (GFAP-TRITC) 
and this effect is enhanced 3 days after the injection, but EGCG potentiated METH-induced 
astrocytic activation on day 3 after METH exposure. (B) Quantification of GFAP shows that 
METH significantly increased astrocytic activation by 198% of the control 1 day after METH 
injection and EGCG+METH-treated has the similar level astrocytic activation. Astrocytic 
activation increased by 303% of control 3 days after METH injection, which is 105% more than 
day 1, and EGCG pretreatment potentiated METH-induced astrocytic activation with 417% 
increase of GFAP immunostaining intensity on day 3. Data represent mean ± SEM values; all data 
were analyzed by Two-way ANOVA followed by Tukey’s multiple comparisons test (n ≥ 7). 
GFAP-TRITC fluorescence of all groups are normalized to the mean of control (saline group). 
****p < 0.0001 EGCG + METH-treated group compared to METH-treated group on day 3 after 
METH exposure. 
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Figure 14. Western blotting shows that EGCG pretreatment potentiated the METH-induced 
GFAP protein level. METH injection caused significant increase of GFAP protein level by 193% 
of the control (saline) 3 days after METH exposure. EGCG pretreatment potentiated METH-
induced increase of GFAP protein by 260% of control, which is 67% more increase of GFAP 
protein level than METH-treated group. Protein loading in each well was normalized by β-actin 
and then normalized to the mean of controls (saline group). *p < 0.05 EGCG + METH-treated 
group compared to METH-treated group, #p < 0.05 METH-treated group compared to saline-
treated group. Data represent mean ± SEM values; all data were analyzed by one-way ANOVA 
followed by Tukey’s multiple comparisons test (n ≥ 7). 
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3.9 EGCG potentiated the METH-induced COX-2 expression 
 
COX-2 is an inducible enzyme and is involved in neuroinflammation. METH exposure 
increases COX-2 levels as an indication of neuroinflammation. To investigate the role of EGCG 
on the METH-induced increase of COX-2 expression, we measured the striatal COX-2 levels by 
immunohistochemistry. There were 8 to 9 CD-1 mice in each of the four groups. We compared 1 
day and 3 days after the METH or saline injection (second injection). The results show that METH 
promoted COX-2 expression 1 day after METH injection as indicated by bright COX-2-FITC 
green fluorescence in METH-treated group (Figure 15A). The statistical analysis show that the 
COX-2 expression in METH-treated group is significantly increased up to 111% of the saline-
treated group on day 1 (p = 0.0005) (Figure 15B). Intriguingly, EGCG + METH-treated group 
potentiated METH-induced COX-2 expression on day 1 as shown in Figure 15A. The statistical 
analysis shows that EGCG pretreated group (EGCG + METH group) increased COX-2 proteins 
level up to 123% of saline-treated group (p < 0.0001), this is significantly higher than METH-
treated group and up to 12% of COX-2 proteins level more than METH-treated group (p = 0.0009) 
(Figure 15B). Injection of EGCG alone did not alter COX-2 proteins level. Three days after the 
METH injection, COX-2 levels in METH-treated group and EGCG+METH-treated group reduced 
to basal level (Figure 15B). One-way ANOVA confirmed that EGCG significantly potentiated 
METH-induced COX-2 expression level on day 1 after METH injection [F(3, 195) = 28.78, p < 
0.0001]. 
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Figure 15. Immunohistochemistry shows that EGCG potentiated METH-induced COX-2 
expression. (A) METH injection increased COX-2 expression as indicated by COX-2-FITC 
fluorescence signal (green) 1 day after METH exposure and EGCG pretreatment enhanced METH-
induced increase of COX-2 expression. These effects were diminished 3 days after METH 
injection. (B) Statistical analysis showed that METH increased COX-2 expression by 110% of the 
control (saline) on day 1 of METH exposure. EGCG pretreatment potentiated METH-induced 
COX-2 expression by 122% of the control on day 1 of METH exposure, which is about 12% more 
than METH-treated group. There were no significant changes among the group on day 3 after 
METH injection. Data represent mean ± SEM values; all data were analyzed by one-way ANOVA 
followed by Tukey’s multiple comparisons test (n ≥ 7). ***p < 0.001 EGCG + METH-treated 
group compared to METH-treated group on day 1 of METH exposure. 
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3.10 EGCG prevented the METH-induced BBB breakdown 
 
The BBB plays an important role in regulating the passage of ions, molecules and cells 
between blood and the brain. METH is known to readily permeate through the BBB and 
compromising the neurovascular structures of the BBB. To identify the effect of EGCG on the 
METH-induced BBB degradation we determined the extravasation of FITC-conjugated dextran 
(FITC-dextran) into the brain. The results of BBB extravasation are compared between one day 
and three days after METH injection. The extravasation occurs when the BBB is damaged and 
thence the FITC-dextran leaks into the brain through the BBB, which can be seen as a patch of 
green fluorescence in the image. Otherwise, only capillaries can be seen on the epifluorescence 
images. One day after METH injection no BBB degradations were present as indicated by no 
apparent patch of green fluorescence in any of the four treatment groups (Figure 16A). However, 
BBB breakdown was significantly increased by METH in METH-treated group 3 days after 
METH injection as indicated by the patches of green fluorescence (Figure 16A). Pretreatment of 
EGCG prevented METH-induced BBB degradation 3 days after METH injection as shown with 
no presence of green patch (Figure 16A). Statistical analysis indicate that METH increased 121% 
of the control (saline-treated group) on day 3 after the METH exposure (p < 0.0001), whereas 
EGCG+METH-treated group has no significant change of permeability of FITC-dextran as 
comparing to the saline-treated group (Figure 16B). Injection of EGCG alone did not show 
significant change of BBB extravasation level (Figure 16 B). One-way ANOVA confirmed the 
significance of BBB extravasation caused by METH injection on day 3 [F(3, 247) = 21.94, p < 
0.0001]. 
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Figure 16. EGCG prevented the METH-induced blood-brain barrier (BBB) extravasation 
on day 3 after METH exposure. Mice were pretreated with EGCG or saline before treatment 
with METH or saline. Mice were intracardially perfused with 10 kDa FITC-dextran, 1 day or 3 
days after METH or saline treatment. (A) Epifluorescence images of FITC-dextran in striatal 
sections showed no FITC-dextran extravasation on day 1 after METH exposure, but BBB leakage 
occurred on day 3 due to METH exposure as indicated by green patches around the capillary 
(arrow). (B) Quantification of FITC-dextran indicates that METH treatment did not affect BBB 
integrity on day 1 after METH treatment, but BBB integrity was significantly decreased as 
indicated by increase of FITC-dextran extravasation, which was prevented by EGCG pretreatment. 
Data represent mean ± SEM values; all data were analyzed by one-way ANOVA followed by 
Tukey’s multiple comparisons test (n ≥ 7). ****p < 0.0001 EGCG + METH-treated group 
compared to METH-treated group on day 3 of METH exposure. 
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CHAPTER 4. DISCUSSION  
 
4.1 METH-induced striatal neurotoxicity and potential drug candidates for the treatment 
 
METH exposure has been shown to damage several regions of the brain, including the 
striatum. The striatum is the main input structure of the basal ganglia utilizing both dopaminergic 
and glutamatergic input systems. Therefore, the striatum is susceptible to METH-induced 
alteration of dopamine levels. The neurotoxic effects of METH in the striatum are, in part, 
associated with its ability to disrupt the dopaminergic system. METH-induced accumulation of 
dopamine promotes several known toxic effects in the brain including oxidative stress, BBB 
breakdown and neuroinflammation (Huang et al., 2013, Snider et al., 2013, Northrop and 
Yamamoto, 2015). The mechanisms of METH-induced neurotoxicity have been well delineated, 
but there is currently no approved treatment for METH. Therefore, it is essential to investigate the 
neuroprotective agents that can potentially target METH-induced neurotoxicity. Our laboratory 
has studied several neuropeptides that are potentially involved in modulation of the METH-
induced neurotoxicity. These studies involved the pharmacological approach, which is using 
synthetic agonists or antagonists. To continue the study of METH-induced neurotoxicity and the 
potential treatment plan, we have searched for natural neuroprotective agents that are effective in 
protecting against neurodegeneration. Green tea catechins are phenolic compounds that possess 
antioxidative properties. There are four types of catechin derivatives found in green tea, and EGCG 
is the most abundant one (Lin et al., 2003). EGCG is a strong antioxidant and its effect is not 
limited to free radical scavenging and iron-chelation. In fact, EGCG has been shown to reduce 
inflammation and promote the regulation of pro-survival genes (AL-amri et al., 2013, Liu et al., 
2014). Thus, EGCG has the potential to protect against the METH-induced neurotoxicity in the 
brain. 
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In a previous study, our lab reported that EGCG effectively attenuated METH-induced 
apoptosis and dopamine terminal damage without preventing the METH-induced hyperthermia in 
mice (Liu et al., 2014). However, the mechanism of EGCG protect against METH-induced striatal 
injury in the striatum is obscure. METH-induced dopamine overflow is one of the leading cause 
to its subsequent neurotoxicity (O'Dell et al., 1993). In addition, dopamine-induced oxidative stress 
caused by METH exposure has been shown to promote severe neuronal damages including 
membrane degradation. Therefore, targeting the METH-induced oxidative stress using EGCG can 
potentially mitigate its neurotoxic effects. First, we investigated the neuroprotective effects of 
EGCG on METH-induced oxidative stress, which can provide us a better insight of the mechanism 
by which EGCG protects striatal tissue from METH.  
4.2 Role of GPx, CAT and SOD on METH-induced oxidative stress 
 
Accumulating evidence suggests that METH can induce oxidative stress by altering the 
balance between reactive oxygen species (ROS) production and the capacity of antioxidant 
enzymatic system (Jayanthi et al., 1998, Harold et al., 2000, Gluck et al., 2001, Chen et al., 2007, 
Horner et al., 2011, Huang et al., 2013). Indeed, METH administration has been shown to alter the 
level of several antioxidative enzymes including GPx, CAT and SOD (Açikgöz et al., 1998, 
Barayuga et al., 2013, Koriem et al., 2013). The reduction of some of these enzymatic activities 
due to METH administration cause increase accumulation of ROS. As a result of ROS 
accumulation, they can react with proteins, lipids and DNA to cause further injury (Wells et al., 
2005).  
In this study we have demonstrated that EGCG prevented the METH-induced reduction of 
striatal GPx activity and GPx protein level. Furthermore, EGCG pretreatment also inhibited the 
METH-induced increase of SOD-1 and CAT proteins level in the striatum. These results are 
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significant in that they provide a substantial evidence that EGCG is involved in protecting against 
METH-induced oxidative stress. GPx family proteins are important in reducing hydrogen peroxide 
and phospholipid hydroperoxides with the consumption of glutathione (GSH) (Brigelius-Flohé, 
2006). The study using SH-SY5Y neuronal cells have shown that METH decrease GPx activity 
along with the reduction of GPx-4 protein levels (Barayuga et al., 2013). Our results appear to be 
consistent with these observations showing that METH significantly reduced GPx activity at 24 hr 
after METH injection in CD-1 mice. Since GPx proteins work in the presence of glutathione, the 
depletion of glutathione within 24 hr after METH administration (Harold et al., 2000, 
Chandramani Shivalingappa et al., 2012) might contribute to the reduction of GPx activity. The 
potent role of GPx is further demonstrated in the study showing that overexpression of GPx in 
PC12 cells can protect against METH-induced neurotoxicity (Hom et al., 1997). On the other hand, 
our data show that the protein level of GPx-4, an isomer of GPx, is also reduced by METH 
exposure. GPx-4 has been thought to involved in prevention of apoptosis by inhibiting the 
accumulation of oxidized lipids, which otherwise can be metabolized by 12/15-lipoxygenase to 
produce products that can promote apoptotic pathway (Seiler et al., 2008). Pretreatment of EGCG 
prevented METH-induced reduction of GPx activity and GPx-4 protein level. Together, these 
results suggest that EGCG may potentially regulate GPx activity and GPx-4 protein level to reduce 
METH-induced oxidative stress. As GPx-4 is involved in prevention of apoptosis, it is also 
suggested that EGCG may mitigate METH-induced apoptosis through regulation of GPx-4 protein 
expression.  
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4.3 Effect of EGCG on METH-induced oxidative stress: as a result of alteration of CAT, 
GPx and SOD activities 
 
In order to better understand the role of EGCG in METH-induced oxidative stress we also 
studied the CAT activity during METH administration. Several studies have demonstrated that 
METH altered CAT activity and CAT protein levels in human, mice and rat (Jayanthi et al., 1998, 
Huang et al., 2013, Koriem et al., 2013). However, these results were contradictory among the 
findings. Jayanthi et al. reported that CAT activity was decreased after injecting METH into mice 
(Jayanthi et al., 1998) while another group observed an increase of CAT activity in human study 
(Huang et al., 2013). One plausible explanation for this discrepancy maybe related to the species 
of animals, the frequency of drug exposure and the time point of measurement (Kate and John, 
2017). Our results demonstrated that METH did not alter striatal CAT protein levels at 8 hr after 
the injection in CD-1 mice. However, the CAT protein levels were significantly increased at 24 hr 
after the injection of METH. Both CAT and GPx reduce hydrogen peroxide, therefore it is possible 
that the increase of CAT protein level at 24 hr after METH injection is compensatory response to 
loss of GPx activity. The time point is also correlated to the previous finding showing that METH 
induce a peak apoptosis at 24 hr after injection of single high dose of METH (30 mg/kg, ip) (Zhu 
et al., 2006c). Pretreatment of EGCG prevented METH-induced increase of CAT protein levels. 
Therefore, it further supports that EGCG may respond to oxidative stress to prevent METH-
induced neurotoxicity. 
In addition to CAT and GPx, SOD-1 also plays an important role during METH-induced 
oxidative stress. SOD-1 is a cytosolic enzyme that catalyze the breakdown of superoxide radicals. 
Açikgöz et al. reported that METH administration increased superoxide dismutase (SOD) activity 
(Açikgöz et al., 1998), suggesting the increase of oxidative stress due to the accumulation of 
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superoxide radicals. In addition, several other studies have also demonstrated the important role 
of SOD-1 by showing that the overexpression of SOD-1 in mice mitigated METH-induced 
neurotoxicity (Cadet et al., 1994, Hirata et al., 1996, Jayanthi et al., 1998). Our results showed that 
administration of METH significantly increased SOD-1 protein levels at 8 hr, but it is not 
significant at 24 hr after METH injection. This result is correlated to the increase of SOD activity 
reported by Açikgöz et al’s group (1998). Intriguingly, EGCG pretreatment prevented METH-
induced increase of SOD-1 protein levels. Together our results suggest that EGCG prevented 
METH-induced oxidative stress, thus ameliorating the damages resulted from METH 
administration. 
4.4 Potentiation of METH-induce microglial and astrocytes activations by EGCG: is it 
neurotrophic or neurotoxic? 
 
Although our results indicate that EGCG protect against METH-induced oxidative stress 
in the striatum, but the benefit of EGCG is not limited to simple free radical scavenging (Salah et 
al., 1995, Lin et al., 1998). For instance, intrathecal EGCG treatment recover the spinal cord injury 
through upregulation of glial-derived neurotrophic factors (Tian et al., 2013). In another study, 
EGCG has been shown to achieve its neuroprotective effect in lipopolysaccharide-induced 
Parkinson’s disease by preventing inflammatory mediators release (AL-amri et al., 2013). 
Therefore, it raises the possibility that EGCG involves in various pathways, not just preventing 
oxidative stress, to protect against METH-induced damages.  
METH-induced neuroinflammation is associated with the activation of glial cells. As 
innate immune cells in the CNS, glial cells also help to support and maintain the homeostasis of 
nervous system. Microglia and astrocytes are most abundant glial cells found in CNS. METH-
induced microglial and astrocytic activations are found in both human and rodent METH abusers. 
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In addition, our lab has demonstrated that a single high dose of METH (30 mg/kg, ip) activate both 
striatal glial cells in mice (Xu et al., 2005). METH-induced glial activations are often associated 
with neuronal injury. For example, LaVoie et al. suggested that microglia activation is the 
contributing factor to METH-induced neurotoxicity based on the observations showing that 
METH-induced microglial activation precedes dopamine terminal damage (LaVoie et al., 2004). 
Thus, it is often suggested that METH-induced glial activations are detrimental.  
Since METH-induced glial activations are associated with neurotoxic effects, EGCG may 
mitigate METH-induced neuronal damages by preventing glial activations. To investigate whether 
EGCG inhibit METH-induced neuroinflammation, glial cell biomarkers Iba-1 (microglia) and 
GFAP (astrocytes) were measured. The results showed that systemic delivery of METH promoted 
microglial activations indicated by increased fluorescent intensity of Iba-1 staining at 24 hr after 
METH injection then returned to basal level 3 days after METH exposure, suggesting the toxic 
effect of METH causes transient neuroinflammation. Further analysis showed that METH-induced 
neuroinflammation promoted morphological changes of microglia as indicated by enlarged cell 
body and increased number of processes. Similarly, METH promoted astrocytic activations as 
indicated by increase of GFAP fluorescent signal at 3 days after METH injection. Unexpectedly, 
pretreatment of EGCG did not prevent METH-induced microglial and astrocytic activations 
instead EGCG potentiated glial activations during METH exposure. Treatment of EGCG alone did 
not induce glial activations, indicating that EGCG does not induce neuroinflammation. However, 
the role of EGCG that potentiated METH-induced neuroinflammation is not clear. But based on 
these observations it raises the possibility that EGCG transiently promoted METH-induced glial 
activations to alleviate neuronal damages. Although chronic METH-induced glial activations may 
contribute to neuronal damages due to phagocytic property of microglia in the later stage, but 
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transient glial activations may be neurotrophic that can potentially prevent further neuronal 
damages caused by METH exposure. In fact, it has been demonstrated that simply inhibit METH-
induced microglial activation using minocycline failed to mitigate METH-induced dopaminergic 
neurotoxicity (Sriram et al., 2006). In general, METH-induced neuroinflammation may contribute 
to adverse effects, but transient neuroinflammation may be necessary for neuronal recovery. 
Potentiation of METH-induced neuroinflammation by EGCG may attribute to cytokines 
release in activated glial cells. Cytokines are made up of significant portion of the immune- and 
neuromodulatory messengers that can be released by activated glial cells (Hanisch, 2002). 
Different types of cytokines have distinct signaling effect, they can induce inflammation (pro-
inflammation) or suppress inflammation (anti-inflammation) (Dinarello, 2000). EGCG is often 
suggested to be an anti-neuroinflammatory mediator. It has been implicated that EGCG protect 
against Alzheimer’s disease through suppression of microglia-induced cytotoxicity (Cascella et al., 
2017). Since EGCG potentiated METH-induced neuroinflammation, its modulation may involve 
in interplay of both pro and anti-inflammatory cytokines. Interestingly, in vitro experiment has 
shown that EGCG increased secretion of several cytokines including IL-1β, IL-6, IL-10, and IL-
12, and decreased IL-17 without affecting normal metabolic activity in the cells (Stavroullakis et 
al., 2018). Therefore, EGCG may modulate METH-induced secretion of inflammatory mediators 
without eliciting the cytotoxic effects. Additionally, EGCG attenuate METH-induced neuronal 
damages is potentially associated with its ability to induce neuroinflammation through modulation 
of cytokines release.  
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4.5 EGCG involved in modulation of COX-2 expression to enhance neuroinflammatory 
response after METH exposure 
 
 
To further dissect the efficacy of EGCG on METH-induced neuroinflammation, we 
investigated the effect of EGCG on COX-2 expression during METH exposure. COX-2 is an 
inducible enzyme, which act as an inflammatory mediator. METH exposure has been shown to 
increase COX-2 expression (Thomas and Kuhn, 2005). Our results showed a corresponding 
increase of COX-2 protein level after METH exposure as indicated by the enhanced FITC-tagged 
COX-2 intensity, and the pretreatment of EGCG potentiated METH-induced COX-2 expression. 
However, it is not clear about the role of EGCG that involved in potentiation of METH-induced 
COX-2 expression. There are studies suggested that COX-2 is essential for METH to exert its 
neurotoxic effects (Thomas and Kuhn, 2005). However, other study showed that selective 
inhibition of COX-2 exacerbates METH-induced dopamine depletion in the striatum of rats 
(Zhang et al., 2007). This is indicated that simply suppress COX-2 expression may contribute to 
neurotoxicity rather than protection, which implicates that increase of COX-2 expression may be 
a necessary process for neuronal recovery. Likewise, EGCG transiently potentiate METH-induced 
neuroinflammation through enhancing COX-2 expression may contribute to neuronal recovery, 
which in turn prevents METH-induced neuronal apoptosis and dopamine terminal damages. 
4.6 EGCG prevented METH-induced BBB disruption, suggesting that EGCG is protecting 
rather than exacerbating METH-induced neurotoxicity 
 
 
The mechanism of METH-induced BBB degradation is not well understood, but the 
consequence of METH exposure on BBB structural alteration has implicated the effect of METH 
on BBB.  It has been shown that METH-induced impairment of BBB is caused by downregulation 
of adherens and tight junctions along with increase expression of both matrix metalloproteinase-2 
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(MMP-2) and matrix metalloproteinase-9 (MMP-9) (Mizoguchi et al., 2007, Mahajan et al., 2008, 
Ramirez et al., 2009b, Eugenin et al., 2013, Hector et al., 2013, Urrutia et al., 2013). In fact, the 
increase activities of MMP-2 and MMP-9 is the potential cause of METH-induced decrease in 
expression of BBB tight junction proteins including occludin, claudin-5, and zonula occluden 
(Martins et al., 2011a). Although these results showed that the neurovascular components of BBB 
are deteriorated by METH administration, but the cause of BBB degradation is obscure. 
The mechanism of METH-induced BBB degradation is consistent to some of the causes 
that lead to BBB disruption in various neurodegenerative diseases, which is partly due to oxidative 
stress and neuroinflammation. The role of oxidative stress in BBB degradation has been studied in 
various disease model. For example, transgenic mice overexpressing copper/zinc superoxide 
dismutase significantly reduce ischemia-induced free radical accumulation and that prevents 
Evans blue extravasation, a technique that measures the BBB integrity (Kim et al., 2001). The 
association of oxidative stress and BBB integrity is further supported by various studies showing 
that attenuation of oxidative stress can mitigate BBB damages due to ischemia and hyperglycemia 
(Kamada et al., 2007, Price et al., 2012, Zehendner et al., 2013). METH-induced increase of 
oxidative stress seems to be involved in alteration of microvascular endothelial structures and 
function, this is supported by the study showing that decrease of ROS by antioxidant, Trolox, 
alleviated METH-induced extravasation of sodium-fluorescein 2 days after METH exposure 
(Ramirez et al., 2009a). METH-induced increase of BBB permeability has been observed in 
hippocampus and amygdala and these effects were recovered by 3 days after METH exposure 
(Bowyer John and Ali, 2006). In our study, we also observed an increase of BBB disruption in the 
striatum 3 days after METH exposure. Interestingly, EGCG pretreatment prevented METH-
induced BBB disruption. The prevention of METH-induced BBB damage by EGCG may be 
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attributed to its ability to suppress METH-induced oxidative stress. This is substantiated by the 
result showing that the prevention of METH-induced alteration of the antioxidative enzymes by 
EGCG antedated the suppression of METH-induced BBB disruption. 
4.7 How does neuroinflammation associate with METH-induced BBB degradation? 
 
METH-induced neuroinflammation is also associated with BBB dysfunction. It has been 
demonstrated in the animal study showing that acute METH treatment stimulate both 
neuroinflammatory response and BBB disruption in mouse hippocampus (Gonçalves et al., 2008, 
Gonçalves et al., 2010, Martins et al., 2011a). The association of neuroinflammation and BBB 
degradation is further supported by the study demonstrating that METH increase the number of 
vascular cells and intercellular adhesion molecules along with the presence of T-cell antigen CD4 
and tissue macrophage marker CD169 in the brain parenchyma (Gonçalves et al., 2017).  
Neuroinflammation may mediate METH-induced BBB disruption through pericyte 
dissociation. This is supported by the study showing that LPS-induced neuroinflammation cause 
the detachment of pericytes from endothelial cells and the basement membrane, which in turn 
increase BBB permeability (Nishioku et al., 2009). Moreover, pro-inflammatory mediators, 
including cyclooxygenases (COX), also play a part in BBB disruption as implicated by the 
treatment of COX-2 inhibitor that prevent traumatic brain injury-induced BBB disruption (Hakan 
et al., 2010). Our observation reveals that EGCG potentiated METH-induced COX-2 expression 
in the striatum and this effect was lasted for one day, but METH-induced BBB degradation 
occurred 3 days after METH exposure and it is prevented by EGCG pretreatment. Together these 
results may suggest that transient increase of COX-2 expression may be protecting against METH-
induced neurotoxicity through increase of neuroinflammatory response. While pathologically 
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increase permeability of BBB by METH could provide an enhanced immune response, but at the 
same time it can have profound adverse effects that elicit severe neuronal damages. 
In summary, the present study shows that the pretreatment of EGCG effectively prevented 
METH-induced oxidative stress by suppressing the alteration of striatal SOD-1, GPx-4 and CAT 
enzymatic activities and proteins level caused by METH exposure. The reduction of METH-
induced oxidative stress by EGCG may be associated with its ability to reduce ROS accumulation. 
On the other hand, EGCG was unable to inhibit METH-induced neuroinflammation instead it 
potentiated astrocyte and microglial activations along with increase COX-2 expression, and 
therefore, protecting against METH-induced BBB degradation. The chronological events on the 
effects of EGCG on METH-induced oxidative stress and neuroinflammation is depicted in Figure 
17. The mechanism involved in potentiation of METH-induced neuroinflammation by EGCG 
pretreatment is obscure. It is unclear whether the potentiation of neuroinflammation contribute to 
METH-induced neurotoxicity. However, it is important to know that simply suppress microglial 
or astrocytic activations is not enough to prevent METH-induced neurotoxicity. Conversely, 
transient activation of glial cells by EGCG may accelerate the neuronal recovery process during 
METH-induced neurotoxicity. In order to further understand the role of EGCG on METH-induced 
neuroinflammation it is suggested to study the levels of cytokines including tumor necrosis factor 
alpha (TNFα) and interleukins (IL). These studies may provide an insight of severity of METH-
induced neuroinflammation at different time points, which is able to impart the efficacy of EGCG 
on METH-induced neuroinflammation. Lastly, EGCG prevented METH-induced BBB leakage, 
which further supports that EGCG is protecting rather than exacerbating METH-induced 
neurotoxicity. 
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Figure 17. Scheme depicting the chronological events of EGCG that modulates METH-
induced neuroinflammation. METH promotes microglial and astrocytic activation along with 
increase of COX-2. METH also causes BBB leakage. However, EGCG potentiates these effects 
caused by METH. EGCG may modulate the regulation of TNFα and IL to regulate METH-induced 
neuroinflammation. Although EGCG potentiated METH-induced neuroinflammation, it protected 
against METH-induced BBB disruption. These results implicate that EGCG is potentially involved 
in more complex biological mechanisms to prevent METH-induced neurotoxicity. 
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